COVID-19 booster dose and pneumonia vaccine can be given at the same time, says Pfizer study
Pharmaceutical company Pfizer said Wednesday that booster doses of its COVID-19 vaccine could be taken along with its pneumonia vaccine. According to a recent study, the company says that taken together strengthens immunity in people aged 65 and older.
The study, launched in May, tested the company’s next-generation conjugated pneumococcal vaccine, PREVNAR 20, with a third dose of Pfizer-BioNTech COVID-19 in 570 participants.
The aim of the study was to test the safety of the combination and the immune response after the addition of the pneumonia vaccine to the existing COVID-19 vaccine.
The company said the responses elicited by PREVNAR 20 and the booster dose of COVID-19 vaccine were similar when given together or with placebo.
The data provide evidence that supports the company's potential to administer PREVNAR 20 and the COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunizations, Pfizer said.
PREVNAR 20 was approved by the U.S. Food and Drug Administration in June last year to help protect adults against most invasive pneumococcal diseases and pneumonia.
Study participants were recruited from the COVID-19 vaccine study in the final phase of companies and those who had received the second dose of the COVID-19 company vaccine at least six months before entering the co-administration study.